Status and phase
Conditions
Treatments
About
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or progressive glioblastoma multiforme.
Full description
OBJECTIVES:
OUTLINE: Patients receive oral erlotinib daily. Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: A total of 73 patients will be accrued for this study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
DISEASE CHARACTERISTICS:
Histologically confirmed glioblastoma multiforme
Radiographic evidence of recurrence or progression
Previously treated with optimal radiotherapy and at least 1 cytotoxic chemotherapy regimen
PATIENT CHARACTERISTICS:
Age
Performance status
Life expectancy
Hematopoietic
Hepatic
Renal
Other
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
No prior epidermal growth factor receptor (EGFR) inhibitor
No concurrent EGFR inhibitor
No other concurrent antineoplastic therapy
No concurrent anti-epileptic agents other than modest- or non-enzyme-inducing drugs such as the following:
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal